LinkedIn facebook twitter youtube
News archive


Although currently there are not approved drugs for the treatment of AL amyloidosis, important data were presented in the European Hematology Association (EHA) Annual congress, held virtually from 11 June to 21 June 2020.

Myeloma Patients Europe (MPE) has interviewed Dr Moshe Gatt, Hadassah Hebrew University Medical Center, Jerusalem (Israel), and one of the authors of the ANDROMEDA study, to summarise the most important updates presented at this meeting for the treatment of the AL amyloidosis patients.

Find below this video below or watch it on our YouTube Channel:



Recent news

» CAR-T cell therapy in myeloma

» Daratumumab subcutaneous, first approved treatment for newly diagnosed AL amyloidosis in Europe

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.